12:00 AM
 | 
Mar 23, 2009
 |  BioCentury  |  Emerging Company Profile

Armune: A signature for prostate cancer

Armune BioScience Inc. believes its serum-based tests for autoantibodies against prostate cancer antigens will provide a more reliable diagnosis than PSA tests, reducing the need for confirmatory biopsies and, for some patients, surgery, radiation and chemotherapy. The company plans to use its own CLIA lab to conduct the assays, which it expects to launch in 2010.

The prostate specific antigen (PSA) test is administered to men over the age of 50 during an annual physical. If a patient has a PSA level >=4 ng/ml, the patient is referred to a urologist for a biopsy.

While the PSA test has sensitivity of about 90%, its specificity is only 30%, President and CEO Eli Thomssen told BioCentury. Thus, "about 70% of the time, the biopsy comes back that the patient does not have cancer," he said.

Armune hopes to reduce the number of unnecessary biopsies with its Armune Test I, which uses a panel of peptides...

Read the full 754 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >